- ISIN
- US09077V1008
- Sector
- Healthcare
- IPO Date
- Sep 26, 2024
Highlights
- Market Cap
- $912.06M
- Enterprise Value
- $676.12M
- EPS (TTM)
- -$2.40
- Total Revenue (TTM)
- $10.32M
- Gross Profit (TTM)
- $7.48M
- EBITDA (TTM)
- -$95.08M
- Year Range
- $4.07 - $24.00
- Target Price
- $45.00
- ROA (TTM)
- -22.62%
- ROE (TTM)
- -23.72%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BIOA Performance Chart
BioAge Labs, Inc (BIOA) is up 62.3% since the beginning of the year. At $21 per share, BIOA is trading 10.5% below its 52-week high of $24.
Loading charts...
Returns By Period
BioAge Labs, Inc (BIOA) has returned 62.28% so far this year and 394.70% over the past 12 months.
BioAge Labs, Inc
- 1D
- 3.37%
- 1M
- 29.26%
- YTD
- 62.28%
- 6M
- 58.10%
- 1Y
- 394.70%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.15%
- 1Y
- 24.03%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
BIOA Monthly Returns History
Based on dividend-adjusted daily data since Sep 26, 2024, BIOA's average daily return is +0.27%, while the average monthly return is +3.72%. At this rate, an investment would double in approximately 1.6 years.
Historically, 64% of months were positive and 36% were negative. The best month was Jan 2026 with a return of +43.5%, while the worst month was Dec 2024 at -69.2%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 3 months.
On a daily basis, BIOA closed higher 50% of trading days. The best single day was Oct 23, 2025 with a return of +31.4%, while the worst single day was Dec 9, 2024 at -76.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 43.54% | 17.27% | -21.46% | -3.66% | 2.61% | 24.18% | 62.28% | ||||||
| 2025 | -20.73% | 0.87% | -18.79% | 11.70% | -5.71% | 4.29% | 6.54% | 12.05% | 19.27% | 28.74% | 25.36% | 39.41% | 128.50% |
| 2024 | -7.56% | 13.46% | -20.34% | -69.20% | -74.27% |
Benchmark Metrics
BioAge Labs, Inc has an annualized alpha of 65.42%, beta of 1.10, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since September 26, 2024.
- This stock participated in 262.11% of S&P 500 Index downside but only 148.46% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 65.42%
- Beta
- 1.10
- R²
- 0.03
- Upside Capture
- 148.46%
- Downside Capture
- 262.11%
Return for Risk
Risk / Return Rank
BIOA ranks 97 for risk / return — in the top 97% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for BioAge Labs, Inc (BIOA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BIOA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.75 | ||
| Sortino ratioReturn per unit of downside risk | +1.85 | ||
| Omega ratioGain probability vs. loss probability | 1.56 | 1.37 | +0.20 |
| Calmar ratioReturn relative to maximum drawdown | 12.03 | 2.78 | +9.25 |
| Martin ratioReturn relative to average drawdown | 28.28 | 12.44 | +15.84 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the BioAge Labs, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BioAge Labs, Inc was 88.23%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current BioAge Labs, Inc drawdown is 16.88%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -88.23%Apr 2025 | 5mo 18d | — | 1y 8moOct 2024 - now |
2024 correction2024 | -18.62%Sep 2024 | 0s | 18d | 18dSep 2024 - Oct 2024 |
2024 pullback2024 | -6.16%Oct 2024 | 1d | 4d | 5dOct 2024 - Oct 2024 |
Drawdown Indicators
| BIOA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -88.23% | -56.78% | -31.45% |
Max Drawdown (1Y)Largest decline over 1 year | -33.07% | -9.10% | -23.97% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -16.88% | -1.80% | -15.08% |
Average DrawdownAverage peak-to-trough decline | -57.58% | -10.71% | -46.87% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.04% | 2.03% | +12.01% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of BioAge Labs, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how BioAge Labs, Inc is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BIOA relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, BIOA has a P/S ratio of 78.1. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BIOA in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, BIOA has a P/B value of 2.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BIOA
Add BioAge Labs, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BIOA